We have located links that may give you full text access.
Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia.
Journal of Infectious Diseases 2019 July 10
Therapy to enhance host immune defenses may improve outcomes in serious infections, especially for antibiotic-resistant pathogens. Recombinant human plasma gelsolin (rhu-pGSN), a normally circulating protein, has beneficial effects in diverse pre-clinical models of inflammation and injury. We evaluated delayed therapy (24-48h post-challenge) with rhu-pGSN in a mouse model of pneumococcal pneumonia. Rhu-pGSN without antibiotics increased survival and reduced morbidity and weight loss after infection with either penicillin-sensitive or resistant pneumococci (serotypes 3 and 14, respectively). Rhu-pGSN improves outcomes in a highly lethal pneumococcal pneumonia model when given after a clinically relevant delay, even in the setting of antimicrobial resistance.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app